IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
Open Access
- 20 December 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1), e000632
- https://doi.org/10.1136/jitc-2020-000632
Abstract
Background As the immune system is compromised in patients with cancer, therapeutic strategies to stimulate immunity appear promising, to avoid relapse and increase long-term overall survival. Interleukin-15 (IL-15) has similar properties to IL-2, but does not cause activation-induced cell death nor activation and proliferation of regulatory T cells (Treg), which makes it a serious candidate for anticancer immunotherapy. However, IL-15 has a short half-life and high doses are needed to achieve responses. Designed to enhance its activity, receptor-linker-IL-15 (RLI) (SO-C101) is a fusion molecule of human IL-15 covalently linked to the human IL-15Rα sushi+ domain currently assessed in a phase I/Ib clinical trial on patients with advanced/metastatic solid cancer. Methods We investigated the antimetastatic activity of RLI in a 4T1 mouse mammary carcinoma that spontaneously metastasizes and evaluated its immunomodulatory role in the metastatic lung microenvironment. We further characterized the proliferation, maturation and cytotoxic functions of natural killer (NK) cells in tumor-free mice treated with RLI. Finally, we explored the effect of RLI on human NK cells from healthy donors and patients with non-small cell lung cancer (NSCLC). Results RLI treatment displayed antimetastatic properties in the 4T1 mouse model. By characterizing the lung microenvironment, we observed that RLI restored the balance between NK cells and neutrophils (CD11b+ Ly6Ghigh Ly6Clow) that massively infiltrate lungs of 4T1-tumor bearing mice. In addition, the ratio between NK cells and Treg was strongly increased by RLI treatment. Further pharmacodynamic studies in tumor-free mice revealed superior proliferative and cytotoxic functions on NK cells after RLI treatment compared with IL-15 alone. Characterization of the maturation stage of NK cells demonstrated that RLI favored accumulation of CD11b+ CD27high KLRG1+ mature NK cells. Finally, RLI demonstrated potent immunostimulatory properties on human NK cells by inducing proliferation and activation of NK cells from healthy donors and enhancing cytotoxic responses to NKp30 crosslinking in NK cells from patients with NSCLC. Conclusions Collectively, our work demonstrates superior activity of RLI compared with rhIL-15 in modulating and activating NK cells and provides additional evidences for a therapeutic strategy using RLI as antimetastatic molecule.Keywords
Funding Information
- Cytune Pharma
- Agence Nationale de la Recherche (ANR-10IBHU-0001, ANR-2011-RPIB-007-05)
- SIRIC SOCRATE (INCa DGOS INSERM 6043)
- Institut National Du Cancer
- Institut National de la Santé et de la Recherche Médicale
- Gustave Roussy Cancer Campus
- Assistance Publique - Hôpitaux de Paris
- Association Nationale de la Recherche et de la Technologie
This publication has 50 references indexed in Scilit:
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunityJCI Insight, 2011
- Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung CarcinomaCancer Research, 2011
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumorsNature Medicine, 2011
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaquesBlood, 2011
- IL-15 transpresentation promotes both human T-cell reconstitution and T-cell–dependent antibody responses in vivoProceedings of the National Academy of Sciences of the United States of America, 2011
- Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Rα complexesProceedings of the National Academy of Sciences of the United States of America, 2010
- Safety and immunologic effects of IL-15 administration in nonhuman primatesBlood, 2009
- Adaptive immune features of natural killer cellsNature, 2009
- IL-15 trans-presentation promotes human NK cell development and differentiation in vivoThe Journal of Experimental Medicine, 2008
- Converting IL-15 to a superagonist by binding to soluble IL-15RαProceedings of the National Academy of Sciences of the United States of America, 2006